Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.

Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L.

J Intern Med. 2013 Apr;273(4):410-21. doi: 10.1111/joim.12032. Epub 2013 Feb 14.

2.

Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.

Arnetz L, Hage C, Ekberg NR, Alvarsson M, Brismar K, Norhammar A, Mellbin L.

Growth Horm IGF Res. 2015 Dec;25(6):298-303. doi: 10.1016/j.ghir.2015.07.009. Epub 2015 Jul 30.

PMID:
26283275
3.

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Jan;14(1):67-76. doi: 10.1111/j.1463-1326.2011.01492.x. Epub 2011 Nov 3.

PMID:
22050786
4.

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.

Alba M, Ahrén B, Inzucchi SE, Guan Y, Mallick M, Xu L, O'Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2013 Dec;15(12):1101-10. doi: 10.1111/dom.12145. Epub 2013 Jul 19.

PMID:
23782502
5.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
6.
7.

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.

PMID:
18476982
8.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
9.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Res Clin Pract. 2012 Oct;98(1):51-60. doi: 10.1016/j.diabres.2012.05.022. Epub 2012 Jun 9.

PMID:
22682949
11.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.

PMID:
17559733
12.

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group.

Diabetes Care. 2006 Dec;29(12):2632-7.

PMID:
17130196
13.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H.

Int J Clin Pract. 2011 Feb;65(2):154-64. doi: 10.1111/j.1742-1241.2010.02589.x.

PMID:
21235696
14.

Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes.

Hage C, Lundman P, Rydén L, Mellbin L.

Eur J Prev Cardiol. 2013 Aug;20(4):549-54. doi: 10.1177/2047487312444371. Epub 2012 Mar 28.

PMID:
22456695
15.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
16.
17.

Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.

Jung JA, Kaku K, Kim JH, Kim JR, Ko JW, Lee SY, Huh W.

Adv Ther. 2013 Nov;30(11):1018-29. doi: 10.1007/s12325-013-0072-x. Epub 2013 Nov 19. Erratum in: Adv Ther. 2014 Jan;31(1):149.

PMID:
24249434
18.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.

Curr Med Res Opin. 2008 Oct;24(10):2943-52. doi: 10.1185/03007990802418851 . Epub 2008 Sep 10.

PMID:
18786299
19.

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E.

J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.

PMID:
22685234
20.

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.

PMID:
17909087

Supplemental Content

Support Center